logo

For the Inventor, By the Inventor

Parlin, NJ, United States of America

Jonathan Brazaitis

USPTO Granted Patents = 9 

Average Co-Inventor Count = 3.1

ph-index = 3

Forward Citations = 72(Granted Patents)


Company Filing History:

goldMedal9 out of 75 
 
Medical Diagnostic Laboratories, LLC
 patents

Years Active: 2013-2022

Loading Chart...
9 patents (USPTO):Explore Patents
1. RE49026 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof (2022-04-11),
2. 10416172 - Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling (2019-09-17),
3. 9868776 - Anti-sense oligonucleotides targeted against exon 9 of IL-23R-alpha gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases (2018-01-16),
4. 9605027 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof (2017-03-28),
5. 9523073 - Elisa for a naturally-occurring soluble truncated form of IL-23 receptor (2016-12-20),
6. 9187750 - Anti-sense oligonucleotides targeted against exon 9 of IL-23Rα gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases (2015-11-17),
7. 9169292 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof (2015-10-27),
8. 8946150 - Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof (2015-02-03),
9. 8618070 - Anti-sense oligonucleotides targeted against exon 9 of IL-23Rα gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases (2013-12-31),

Title: Innovations by Jonathan Brazaitis

Introduction

Jonathan Brazaitis is a notable inventor based in Parlin, NJ (US). He has made significant contributions to the field of medical diagnostics and therapeutic applications, holding a total of 9 patents. His work primarily focuses on polypeptides and their role in inhibiting cell signaling related to various human diseases.

Latest Patents

One of his latest patents involves polypeptides that bind to the IL-23 receptor, inhibiting the binding of IL-23 and its associated cell signaling. This invention presents novel linear and cyclic polypeptides with a core structure of WXXXW, where W represents tryptophan, and X represents other amino acids. The preferred core structures include WVDYW or WQDYW. This invention has potential applications in treating IL-23 associated diseases such as inflammatory bowel diseases, psoriasis, and multiple sclerosis.

Another significant patent by Brazaitis is related to a recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling. This invention describes an isolated naturally-occurring soluble truncated IL-23Rα protein, which can serve as a diagnostic tool for autoimmune diseases, including Crohn's disease. The therapeutic applications of this protein are particularly promising for patients suffering from Crohn's disease.

Career Highlights

Jonathan Brazaitis is currently associated with Medical Diagnostic Laboratories, LLC, where he continues to innovate in the field of medical diagnostics. His work has been instrumental in developing solutions that address critical health issues.

Collaborations

Brazaitis has collaborated with notable colleagues such as Grant E Gallagher and Raymond Yu, contributing to the advancement of medical research and diagnostics.

Conclusion

Jonathan Brazaitis is a distinguished inventor whose work in polypeptides and IL-23 receptor signaling has the potential to significantly impact the treatment of various human diseases. His contributions to medical diagnostics and therapeutic applications are noteworthy and continue to pave the way for future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…